Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
554.00    0.00 (0.00%)
Bid:
554.50
Ask:
555.00
Spread: 0.50 (0.09%)
Market Cap: £2.45b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Director/PDMR Shareholding

24 Nov 2017 12:54

Tate & Lyle PLC

Notification of transaction by Persons Discharging Managerial Responsibilities

Tate & Lyle PLC (the ‘Company’) announces that in accordance with the incentive arrangements relating to the recruitment of Melissa Law, President, Global Operations, and Andrew Taylor, President, Innovation and Commercial Development (who both joined the Company in September 2017) a grant of awards over the Company’s ordinary shares of 25 pence each in the capital of the Company (‘Shares’) was made today as detailed in the table below:

Person discharging managerial responsibilities (‘PDMR’) Performance Share Plan (‘PSP’) Restricted Share Award (‘RSA’)
Melissa Law 150,491 22,597
Andrew Taylor 163,200 45,193

The PSP Award is subject to the performance conditions that apply to awards made under the Performance Share Plan 2012 during the year ending 31 March 2018 and accordingly will only vest to the extent that these performance conditions are satisfied by the Company over a three-year performance period which runs from 1 April 2017 to 31 March 2020. These criteria are described in the Annual Report 2017. No consideration is payable for the grant or release of the awards.

The notifications below, which have been made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail.

Claire-Marie O’Grady

Company Secretary

24 November 2017

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Details of PDMR / person closely associated with them (“PCA”)
a) Name Melissa Law
2. Reason for the notification
a) Position / status PDMR – President, Global Operations
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Tate & Lyle PLC
b) LEI 2138008K14474WPKZ244
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code

Ordinary shares of 25 pence each in the capital of Tate & Lyle PLC

GB0008754136

b) Nature of the transaction Grant of a conditional award over shares for no consideration under the Tate & Lyle Performance Share Plan 2012 and Restricted Share Award programme
c) Price(s) and volume(s)

Price(s) Volume(s)

Nil 173,088

d) Aggregated information

Aggregated volume Price

173,088

Nil

e) Date of the transaction 2017-11-24
f) Place of the transaction Outside a trading venue

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Details of PDMR / person closely associated with them (“PCA”)
a) Name Andrew Taylor
2. Reason for the notification
a) Position / status PDMR – President, Innovation and Commercial Development
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Tate & Lyle PLC
b) LEI 2138008K14474WPKZ244
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code

Ordinary shares of 25 pence each in the capital of Tate & Lyle PLC

GB0008754136

b) Nature of the transaction Grant of a conditional award over shares for no consideration under the Tate & Lyle Performance Share Plan 2012 and Restricted Share Award programme
c) Price(s) and volume(s)

Price(s) Volume(s)

Nil 208,393

d) Aggregated information

Aggregated volume Price

208,393

Nil

e) Date of the transaction 2017-11-24
f) Place of the transaction Outside a trading venue

View source version on businesswire.com: http://www.businesswire.com/news/home/20171124005128/en/

Copyright Business Wire 2017

Date   Source Headline
21st Oct 20253:30 pmRNSHolding(s) in Company
16th Oct 202512:00 pmRNSHolding(s) in Company
8th Oct 202512:00 pmRNSHolding(s) in Company
6th Oct 20254:30 pmRNSDirector/PDMR Shareholding
6th Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 202510:00 amRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSPre-close statement
2nd Sep 20258:00 amRNSTotal Voting Rights
11th Aug 20251:00 pmRNSDirector/PDMR Shareholding
5th Aug 20257:00 amRNSDirector/PDMR Shareholding
1st Aug 202511:00 amRNSTotal Voting Rights
24th Jul 20252:30 pmRNSResult of Annual General Meeting 2025
15th Jul 20251:00 pmRNSDirector/PDMR Shareholding
1st Jul 20253:30 pmRNSBlock listing Interim Review
1st Jul 20257:00 amRNSTate & Lyle Capital Markets Event
13th Jun 20253:00 pmRNSHolding(s) in Company
11th Jun 20254:30 pmRNSDirector/PDMR Shareholding
5th Jun 20252:30 pmRNSAnnual Financial Report and Notice of Meeting 2025
5th Jun 20252:00 pmRNSDirector/PDMR Shareholding
2nd Jun 202512:30 pmRNSTotal Voting Rights
28th May 202512:00 pmRNSDirector/PDMR Shareholding
27th May 202512:00 pmRNSDirector/PDMR Shareholding
23rd May 202510:00 amRNSDirector/PDMR Shareholding
22nd May 20257:00 amRNSFinal Results
14th May 20259:00 amRNSHolding(s) in Company
1st May 20253:00 pmRNSHolding(s) in Company
29th Apr 20253:30 pmRNSHolding(s) in Company
28th Apr 20255:15 pmRNSHolding(s) in Company
24th Apr 202512:00 pmRNSHolding(s) in Company
15th Apr 20257:00 amRNSIntegration update and pre-close statement
27th Mar 20257:00 amRNSDirectorate Change
14th Mar 202510:05 amRNSDirectorate declaration
11th Mar 20253:00 pmRNSHolding(s) in Company
5th Mar 202511:30 amRNSDirector/PDMR Shareholding
28th Feb 20254:30 pmRNSHolding(s) in Company
28th Feb 202510:15 amRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSAdditional Listing
20th Feb 20251:42 pmRNSDirector/PDMR Shareholding
13th Feb 20257:00 amRNSTrading Statement
4th Feb 20257:05 amRNSDirector Declaration
3rd Feb 20253:30 pmRNSTotal Voting Rights
23rd Jan 20255:30 pmRNSIssue of Debt
9th Jan 20255:54 pmRNSCompletion of Share Buyback Programme
9th Jan 20255:45 pmRNSTransaction in Own Shares
8th Jan 20255:17 pmRNSTransaction in Own Shares
8th Jan 20252:02 pmRNSDirector/PDMR Shareholding
7th Jan 20255:31 pmRNSTransaction in Own Shares
6th Jan 20256:10 pmRNSTransaction in Own Shares
6th Jan 20252:00 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.